IACP Town Hall on Wednesday, August 7, 2013, 2 pm EST. David Miller and Sarah Dodge will provide S. 959 update, and share IACP CAMP!
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Thursday, August 1, 2013
Texas prison system running out of execution drug By MICHAEL GRACZYK, Associated Press | August 1, 2013 | Updated: August 1, 2013 1:33pm
HUNTSVILLE, Texas (AP) — The nation's most active death penalty state is running out of its execution drug.
The Texas Department of Criminal Justice said Thursday that its remaining supply of pentobarbital expires in September and that no alternatives have been found. It wasn't immediately clear whether two executions scheduled for next month would be delayed. The state has already executed 11 death-row inmates this year, and at least seven more have execution dates in coming months.
"We will be unable to use our current supply of pentobarbital after it expires," agency spokesman Jason Clarksaid. "We are exploring all options at this time."
Texas switched to the lethal, single-dose sedative last year after one of the drugs used in its three-drug execution process became difficult to obtain and the state's supply expired. Other death-penalty states have encountered similar problems after some drug suppliers barred the drugs' use for executions or have refused, under pressure from death-penalty opponents, to sell or manufacture drugs for use in executions.
No executions in Texas were delayed because of that shortfall. But because the shortage is now affecting such an aggressive death-penalty state, the effects could move beyond Texas.
continue to read here
Louisiana Board of Pharmacy Board Meeting Agenda for August 14, 2013
NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for 10:00
a.m. on Wednesday, August 14, 2013 at the Board office, for the purpose to wit:
A G E N D A
NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.
Revised 07-31-2013
1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items
5. Consideration of Minutes
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
9. Committee Reports
A. Finance – Mr. Russell Champagne, CPA & Mr. Pitre
• Consideration of Final Report for Fiscal Year 2012-2013
• Consideration of Budget Amendment No. 1 for Fiscal Year 2013-2014
B. Application Review – Ms. Melancon
• Consideration of Committee Recommendations re Applications
C. Reciprocity – Ms. Hall
• Consideration of Committee Recommendations re Applications
D. Violations – Mr. Bond
• Consideration of Proposed Voluntary Consent Agreements
E. Impairment – Mr. Rabb
• Consideration of Committee Recommendations re Applications
F. Reinstatement – Ms. Melancon
• Consideration of Committee Recommendations re Applications
G. Tripartite – Mr. Burch
H. Regulation Revision – Mr. McKay
• Consideration of Comments from May 30 Public Hearing
I. Executive – Mr. Aron
• Consideration of Committee Recommendations re Policies & Procedures
10. Staff Reports
J. Prescription Monitoring Program – Mr. Fontenot
K. General Counsel – Mr. Finalet
L. Executive Director – Mr. Broussard
• Consideration of Annual Report
• Consideration of Louisiana Compliance Questionnaire
• Consideration of Colleges & Schools of Pharmacy
11. Request for Opinion: Addition of Medications by Non-Pharmacy Practitioners to Parenteral Preparations Previously Compounded by Pharmacies (BioScrip®)
12. Announcements
13. Recess
Louisiana Board of Pharmacy Meetings in August 2013
08-15-2013 Administrative Hearing
08-14-2013 Board Meeting
08-14-2013 Reciprocity Committee
08-13-2013 Executive Committee
08-13-2013 Impairment Committee
08-13-2013 Reinstatement Committee
08-13-2013 Finance Committee
08-14-2013 Board Meeting
08-14-2013 Reciprocity Committee
08-13-2013 Executive Committee
08-13-2013 Impairment Committee
08-13-2013 Reinstatement Committee
08-13-2013 Finance Committee
Compounding Legislation’s Rationale Gets Boost From GAO – But Its Details Don’t
By Cathy Dombrowski / Email the Author / Jul. 31, 2013
Word Count: 903 / Article # 14130731005 / Posted: July 31 2013 8:00 PM
Executive Summary
A report from the federal watchdog agency backs up FDA’s quest for legislative action, but makes no specific recommendations on how to improve the agency’s capabilities to regulate compounding pharmacies.
Study: Compounding pharmacy oversight inconsistent
BOSTON (AP) — A new federal report has concluded that the authority to regulate pharmacies engaged in drug compounding is ‘‘unclear’’ and ‘‘inconsistent’’ at the state and federal levels.
The Government Accountability Office also found that federal circuit court decisions have given the Food and Drug Administration different oversight authority in different parts of the country.
continue to read here
Subscribe to:
Posts (Atom)